JMAR Enters into Distribution Agreement With GMP Systems
"We are pleased to introduce GMP Systems as our first distributor for the pharmaceutical industry," said Ron Walrod, CEO and president of JMAR. "Our initial laboratory tests suggest that BioSentry will be effective in detecting and classifying bacteria in pharmaceutical process water. We look forward to utilizing GMP's experience and long-standing relationships to help us speed our entry into this large addressable market."
“We are pleased to introduce GMP Systems as our first distributor for the pharmaceutical industry”
BioSentry is a contamination warning system for waterborne microorganisms. Whereas current water monitoring depends on batch sampling of water and time-consuming lab analysis, BioSentry uses laser-based technology to provide continuous, online, real-time monitoring for harmful bacteria and protozoa. BioSentry is targeted towards a number of applications across multiple industries, including municipal drinking water utilities, the beverage industry, and homeland security.
JMAR Technologies, Inc. is a leading innovator in the development of laser-based equipment for imaging, analysis and fabrication at the nano-scale. The Company is leveraging more than a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries while continuing to carry out work under U.S. Government contracts. JMAR is targeting the nanotechnology, bioscience and semiconductor industries with its BriteLight(TM) Laser; X-ray Light Source; Compact X-ray Microscope -- for 3D visualization of single cells and polymers; and X-ray Nano Probe -- enabling interaction, analysis and materials modification at the nano-scale. JMAR also develops, manufactures and markets its BioSentry(TM) microorganism early-warning system and maintains a strategic alliance for the production of the READ chemical sensor for the homeland security, environmental and utility infrastructure industries.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR's facility, delays in completion of the X-ray Microscope and X-ray Nano Probe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets , cost and margins for JMAR's products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-Q for the quarter ended September 30, 2005 and its Form 8-K filed on March 30, 2005 with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.